Factor In the Initial Resuscitation of Severe Trauma 2 Patients — FiiRST-2  

Coagulopathy Clinical Trial

Official title: Prospective, Multi-center, Randomized, Parallel-control, Superiority Study Comparing Administration of Clotting Factor Concentrates With a Standard Massive Hemorrhage Protocol in Severely Bleeding Trauma Patients.

Status Recruiting

Clinical Trial Summary

Injury is the leading cause of death for people between the ages of 1-44. This is especially true in trauma patients who have bleeding complications. Acute trauma coagulopathy (ATC) is associated with high transfusion requirements, longer ICU stays, and a greater incidence of multi-organ dysfunction. The cause of coagulopathy is multi-factorial.

One major driver is acquired fibrinogen deficiency (hypofibrinogenemia). Fibrinogen is critical in clot formation and enhances platelet aggregation. Due to the body's limited reserve, it is the first clotting factor to fall to critical levels during life-threatening bleeding. This can impair coagulation and increases bleeding complications. There are two primary options available for fibrinogen supplementation:

• Cryoprecipitate- North American standard

• Fibrinogen Concentrate (FC)- European standard

Consumption of coagulation factors, including fibrinogen, is another important component of ATC. To replenish these depleted coagulation factors and improve thrombin generation, two therapies are available:

• Frozen Plasma (FP)- North American standard

• Prothrombin Complex Concentrate (PCC)- European standard

Strategies for hemorrhage and coagulopathy treatment have changed significantly over the last decade. Prompt hemorrhage control, along with targeted coagulation factor replacement, are emerging as key components of trauma care. Currently, the initiation of a massive hemorrhage protocol (MHP) results in red blood cells (RBCs) and FP transfusions in a 1:1 or 2:1 ratio. Clotting factors are replaced via FP administration. Fibrinogen supplementation is administration after lab verification or at the clinician's discretion. MHP continues until the rate of hemorrhage is under control.

FC and PCC have several important advantages over cryoprecipitate and FP but there is a scarcity of data regarding their efficacy and safety of their use in hemorrhaging trauma patients. The FiiRST-2 study aims to understand if early use of FC and PCC in trauma patients at risk of massive hemorrhage will lead to superior patient outcomes. This trial will also provide safety data on early administration of FC and PCC as a first-line hemostatic therapy in trauma care, and its impact on hemostatic and other clinical endpoints.

Clinical Trial Description

Study Design and Duration FiiRST-2 is a multicenter, randomized, parallel-control, superiority trial, utilizing a conventional two-armed, two-stage design, with an adaptive interim analysis, performed at Level 1 Trauma Centers in Canada. The study is designed to examine the effect of replacing fibrinogen and clotting factors via FC and PCC following activation of the massive hemorrhage protocol (MHP) on the number of ABP units transfused in trauma patients with severe hemorrhage versus the current standard of care (ratio-based plasma resuscitation).

Test Products, Dose, and Mode of Administration:

Patients will be randomized if the MHP is activated according to the MHP activation criteria at each study site. Once eligibility is confirmed, the blood bank medical laboratory technologist will randomize the patient to one of two groups: the intervention group or the control group.

• Intervention group: 4 g Fibryga and 2000 IU Octaplex will be released as part of the first and second MHP packs.

• Control group: 4 U FP will be released as part of the first and second MHP packs.

• Concomitant therapy: In both groups, 4 U RBC will be included as part of the first and second MHP packs, and 1 dose of platelets (4 U of pooled random donor or single donor apheresis) will also be included as part of the second MHP pack. Both RBCs and platelets will be administered according to the clinical situation and/or lab results as per the discretion of the clinical team. The second MHP pack will be released at the request of the clinical team, but clinicians will be instructed to administer all of the investigational product (Fibryga/Octaplex or FP) in the first pack before moving onto the second pack. Similarly, if the second pack is opened, clinicians will be instructed to administer all of the investigational products contained within, before moving to the third pack. Not administering all of the investigational products in the first pack, once started, will be a protocol deviation.

Administration of all non-investigational products will be at the discretion of the clinical team according to the hemodynamic status of the patient and/or laboratory results (standard and/or point-of-care as per institutional practice). While platelets will be routinely included in the second pack, clinicians can request platelets outside of the packs (e.g., for patients on antiplatelet therapy or with marked thrombocytopenia). In the control group, FC may be administered if hypofibrinogenemia (fibrinogen level below 1.5-2.0 g/L or FIBTEM A10 below 8-12 mm) is identified as part of routine testing, at the discretion of the clinical team. Patients in the intervention group can receive additional FC if hypofibrinogenemia (as per above criteria) is identified after the full dose (4g) in the first pack is administered (if the second pack is not opened). If the second pack is opened, additional doses of FC will be permitted after the full dose (4g) in the second pack is administered..

Patients in the control group will not be permitted to receive PCC during the study. Patients in the intervention group may receive FP in the third and subsequent MHP packs. If a third MHP pack is required, and thereafter, MHP packs will contain ABPs (RBCs, platelets and plasma) according to guidelines at each participating site or revert to laboratory-guided transfusion as per the local guidelines once bleeding is controlled. The MHP should be terminated once bleeding is controlled and the MHP criteria are no longer met. Termination of the MHP may occur at any time based on the discretion of the clinical team.

The maximum time frame for administration of the second MHP pack (if required) for both groups is 24 hours from arrival to the trauma bay/ED or termination of the MHP (whichever comes first).

We anticipate for the trial to begin in June 2020 and be completed over a 3 year period.

Sample Size The study will enroll up to 350 trauma patients with approximately 175 assigned to each of the two treatment groups.

Due to the inherent variability in the primary endpoint and a yet substantial uncertainty about the effect size, an adaptive design approach will be used. For this, a planned interim analysis will be performed after 120 patients have completed the study at up to four hospital sites. Primary aim of this interim analysis is to calculate the p-value and conditional power of the test statistic and perform a sample size re-assessment. This will be done in an unblinded interim analysis performed by an independent statistician who will report the results only to the independent data safety monitoring committee (IDSMC) which will make recommendations to the sponsor without revealing the treatment groups. Hence, the final number of enrolled patients will depend on the sample size re-calculation. ;

Related Conditions & MeSH terms

• Blood Coagulation Disorders
• Coagulopathy
• Hemorrhage
• Hemostatic Disorders
• Massive Hemorrhage
• Traumatic Hemorrhage

• NCT number: NCT04534751
• Study type: Interventional
• Source: University Health Network, Toronto
• Contact: Jo Carroll, RN
• Phone: 416-340-4800
• Email: Jo.Carroll@uhn.ca
• Status: Recruiting
• Phase: Phase 4
• Start date: April 1, 2021
• Completion date: January 30, 2024